Arcus reports 35-month median overall survival for casdatifan in late-line kidney cancer study

• Arcus Biosciences presented new ARC-20 trial results supporting investigational casdatifan across treatment settings in clear cell kidney cancer.
• First-line casdatifan with zimberelimab delayed progression more than immunotherapy benchmarks; Phase 3 PEAK-20 remains on track to start in fourth-quarter 2026.
• Second-line casdatifan with cabozantinib exceeded cabozantinib monotherapy survival benchmarks, supporting the ongoing Phase 3 PEAK-1 trial.
• Late-line casdatifan monotherapy exceeded survival benchmarks for the only approved HIF-2α inhibitor, supporting plans for a registrational trial with tivozanib.
• No unexpected safety signals emerged across the reported cohorts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610200830BIZWIRE_USPR_____20261020_BW714807) on October 20, 2026, and is solely responsible for the information contained therein.